Evidence map›Paper›PMID 42084699›Full record

ArticleMolecular biology reports2026

Rational construction of rpsL or/and rpoB merodiploids affects biosynthesis of secondary metabolite in Streptomyces.

Chen Lu, Xiaoyu Pan, Shiying Yang, Jinyao Zhang, Yujie Jiang, Yongyong Zhang, Andreas Bechthold, Zheng Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chen Lu *Key Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Xiaoyu Pan *Key Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Shiying YangKey Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Jinyao ZhangKey Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Yujie JiangKey Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Yongyong ZhangKey Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China.
Andreas BechtholdInstitute for Pharmaceutical Sciences, Pharmaceutical Biology and Biotechnology, University of Freiburg, 79104, Freiburg, Germany.
Zheng MaKey Laboratory of Microbiological Metrology, Measurement & Bio-product Quality Security, State Administration for Market Regulation, College of Life Sciences, Jiliang University, Hangzhou, 310018, Zhejiang Province, China. mazheng520@163.com.ORCID http://orcid.org/0000-0002-1446-0708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRibosome engineering technology typically involves resistance screening of streptomycin and rifampin to introduce point mutations in genes ribosomal protein S12 (rpsL) or RNA polymerase (rpoB), thereby enhancing the synthesis level of secondary metabolites in Streptomyces. Currently, directly introducing copies of genes rpsL and rpoB carrying "beneficial mutations" to construct diploids has become a more rapid and efficient method for obtaining high-yielding Streptomyces strains. METHODS AND

resultsWe directly introduced these beneficial mutations (rpsL: K88E/P91S; rpoB: S433L/H437Y/R440C) to construct single or combined merodiploids. Introducing rpsL-K88E promoted secondary metabolite biosynthesis in both strains S. coelicolor M145 and S. diastatochromogenes 1628, notably increasing tetramycin A production by 66% in 1628-rpsL-K88E. However, rpsL-P91S yielded no significant positive effects. Regarding rpoB, the M145-rpoB-H437Y strain showed a modest enhancement, with actinorhodin and undecylprodigiosin yields increasing by 20% and 22%. In S. diastatochromogenes 1628, introducing rpoB-H437Y, rpoB-R440C and rpoB-S433L promoted the synthesis of toyocamycin and tetraene macrolides to varying degrees.

conclusionsConstructing a diploid by directly introducing the rpsL and rpoB genes carrying "beneficial mutations" is an effective strategy to enhance the synthesis level of secondary metabolites, whether for the model strain S. coelicolor M145 or the industrial strain S. diastatochromogenes 1628.

Indexed as

Bacterial ProteinsDNA-Directed RNA PolymerasesRibosomal ProteinsSecondary MetabolismStreptomycesAnthraquinonesBenzoisochromanequinonesMutationRibosomesStreptomyces coelicoloractinorhodinAnthraquinonesBacterial ProteinsBenzoisochromanequinonesDNA-Directed RNA PolymerasesRibosomal Proteinsribosomal protein S12Ribosome engineeringRpoBRpsLStreptomyces coelicolor M145Streptomyces diastatochromogenes 1628

Identifiers

PMID42084699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.